Effects of Budesonfor Inhalation and Doxofylline Aerosol Inhalation in the Treatment of Severe Bronchial Asthma
Objective To study the effects of budesonfor inhalation and doxofylline aerosol inhalation in the treatment of severe bronchial asthma.Methods A total of 110 patients with severe bronchial asthma admitted to Henan Electric Power Hospital from January 2020 to July 2021 were selected and divided into a control group and an observation group according to the random number table method,with 55 cases in each group.All patients were treated with standard treatment.The control group was treated with doxofylline aerosol inhalation,and the observation group was treated with budesonfor inhalation on the basis of doxofylline injection.The clinical efficacy,lung function,respiratory mechanics,inflammatory factors,metabolomics indexes and adverse reactions were compared between the two groups.Results After treatment,the clinical effective rate of observation group was higher than that of control group(80.00％vs.61.82％,P＜0.05).Lung function was improved in both groups,and peak expiratory flow(PEF),forced expiratory volume in one second(FEV1)and forced vital capacity(FVC)in observation group were higher than those in control group(P＜0.05).The values of work of breathing(WOB),peak inspiratory pressure(PIP)and airway resistance(Raw)were decreased,while the dynamic compliance(Cdyn)was increased(P＜0.05).WOB,PIP and Raw in observation group were lower than those in control group,and Cdyn was higher than that in control group(P＜0.05).The levels of inflammatory factors were decreased in both groups,and interleukin-10(IL-10),tumor necrosis factor-α(TNF-α)and C-reactive protein(CRP)in observation group were lower than those in control group(P＜0.05).The metabolomic indexes of the two groups were decreased,and the acetoacetic acid,isoleucine and glutamic acid of the observation group were lower than those of the control group(P＜0.05).There was no statistical difference in the incidence of adverse reactions between the two groups(P＞0.05).Conclusion Budigforol combined with doxofylline aerosol inhalation can effectively improve the clinical efficacy,enhance lung function and respiratory capacity,eliminate inflammatory factors,correct the expression of metabolic indicators,and is safe and effective.
万方数据
维普
